-
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study
van der Voort, A., Louis, F. M., van Ramshorst, M. S., Kessels, R., Mandjes, I. A., Kemper, I., Agterof, M. J., van der Steeg, W. A., Heijns, J. B., van Bekkum, M. L., Siemerink, E. J., Kuijer, P. M., Scholten, A., Wesseling, J., Vrancken Peeters, M-J. T. F. D., Mann, R. M., Sonke, G. S. & Dutch Breast Cancer Research Group, 1 May 2024, In: The Lancet Oncology. 25, 5, p. 603-613 11 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Tailoring systemic treatment in HER2-positive breast cancer
van der Voort, A., 2024, 223 p.Research output: PhD Thesis › Phd-Thesis - Research and graduation internal
-
Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival
van der Voort, A., Liefaard, M. C., van Ramshorst, M. S., van Werkhoven, E., Sanders, J., Wesseling, J., Scholten, A., Vrancken Peeters, M. J. T. F. D., de Munck, L., Siesling, S. & Sonke, G. S., 1 Oct 2022, In: Breast (Edinburgh, Scotland). 65, p. 110-115 6 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
